Could this mean an end to Cataract Surgery?

Latest News Services Circuits Contact Us Archives Subscribe Search

FOR IMMEDIATE RELEASE

COULD THIS MEAN AN END TO CATARACT SURGERY?

TAGERWILEN, Switzerland, February 10, 2005 --/WORLD-WIRE/-- A revolutionary new treatment for cataracts has been gaining in popularity here in Europe since it was featured over in the UK on the Richard & Judy Television Show last year with amazing results. Ethos GmbH Schweiz, the Swiss manufacturers, claim 'This could mean an end to cataract surgery'.

The product, called Ethos Endymion "Bright Eyes", uses a special derivative of the naturally occurring neuropeptide L-Carnosine, called N-Acetyl-Carnosine (NAC), which is a super antioxidant and anti-glycating agent. NAC, when topically applied, can penetrate and protect the lipid tissues of the eye against light damage and also helps to diminish free radical damage and the harmful effects of glycosylation associated with degenerative eye disease.

Cataract is a major problem globally; 17 million people around the world are blind because of cataracts and 28,000 new cases are reported every day. Approximately 25% of the population over 65 (and about 50% over 80) have a serious loss of vision due to cataracts.

At any one time in the UK alone there are over 500,000 people awaiting cataract surgery and the figures for the rest of Europe are frightening. One leading London Hospital over in the UK carries out between 250 and 500 cataract operations a week! The backlog is proving to be such a big problem for them that now, Cataract Units are being drafted in from abroad to help to address their very worrying situation.

Professor Steven Charles Gallant, the world renowned biochemist who was originally responsible for introducing Bright Eyes to Europe says; "I have been studying the effects of L-Carnosine for many years. It was first discovered back in 1988 that N-Acetyl-Carnosine had positive effects on cataracts. My father had cataracts and did not relish going under the knife so I tried to get some for him but unfortunately, at the time, it wasn't easily obtainable. My father had to have the operation, which thankfully was successful. But that got me to thinking how great it would be if we were to develop, and make readily available, a product whereby this condition could be addressed with a simple course of eye drops as opposed to surgery. After many years' research, development and trials of Bright Eyes, many people are now enjoying much-improved vision due to this exciting medical breakthrough."

One of the clinical trials carried out in China, on 96 patients with cataracts of varying degrees of severity, showed a profound effect; with the effective rate being 100% on primary senile cataract and 80% for mature senile cataract over the 6 month trial period. Positive effects were also observed with other types of cataract. Another trial indicated an eye condition improvement of 41.5% to 100% for patients within a 6-month period, with sustainable results 24-months later.

A box of Bright Eyes costs 100 Swiss francs (approximately 50 or €75) and contains 5 x 2ml vials which is roughly a month's supply when using two drops a day in each eye. With the majority of people seeing positive results over a 3-6 month period, it is a relatively inexpensive course of treatment when you consider that a cataract operation costs over 4,000 Swiss francs (approximately £2,000 or €3,000) for one eye, and over 7,500 Swiss francs (approximately £3,500 or €5,000) for both.

For More Information Visit: www.ethos.ag

CONTACT:
Herr Simon Howlett
Ethos GmbH Schweiz
Hauptstr. 46
CH-8274 Tägerwilen
Switzerland

E-mail: simon@ethos.ag

Tel: +41 (0)71 669 1440
Fax: +41 (0)12 742 827

World-Wire is a resource provided by Environment News Service
To Unsubscribe or Change Account Settings: Click here